Abstract
Uterine leiomyomata are the most common benign tumors in women, occurring in 20%–25% of women during their reproductive years. The etiology of myomas has not been fully elucidated. Growth of leiomyomas is promoted by various factors. Hypoestrogenism, which occurs after the postmenopause and during therapy with gonadotropin-releasing hormone (GnRH) agonist, reduces the size of leiomyomas; this observation indicates that the tumor is estrogen dependent (1). Similarly, marked regression of leiomyomas after therapy with the potent antiprogestin RU486 indicates a probable stimulatory effect of progesterone on the tumor (2). Increasing evidence shows that growth factors may play a role in the generation or growth of this tumor.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
